Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity: 2014-2024

Historic Common Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $671.6 million.

  • Viridian Therapeutics, Inc.\DE's Common Equity fell 28.91% to $503.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.0 million, marking a year-over-year decrease of 28.91%. This contributed to the annual value of $671.6 million for FY2024, which is 51.95% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Common Equity of $671.6 million as of FY2024, which was up 51.95% from $442.0 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Common Equity peaked at $671.6 million during FY2024, and registered a low of $120.0 million during FY2020.
  • Its 3-year average for Common Equity is $502.9 million, with a median of $442.0 million in 2023.
  • Data for Viridian Therapeutics, Inc.\DE's Common Equity shows a peak YoY skyrocketed of 661.95% (in 2020) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Common Equity (Yearly) stood at $120.0 million in 2020, then skyrocketed by 56.38% to $187.7 million in 2021, then surged by 110.46% to $395.1 million in 2022, then climbed by 11.89% to $442.0 million in 2023, then surged by 51.95% to $671.6 million in 2024.